Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals

Abstract The US Food and Drug Administration approves tissue-agnostic therapies to target tumor biomarkers regardless of tumor type. In light of the growing number of such approvals in recent years, a better understanding of their relative clinical benefit across cancer types is required. To address...

Description complète

Détails bibliographiques

Auteurs principaux:	George W. Sledge, Takayuki Yoshino, Joanne Xiu, Anthony Helmstetter, Jennifer R. Ribeiro, Sergey Klimov, Brady Gilg, JJ Gao, Jeff Elton, Matthew J. Oberley, Milan Radovich, Jim Abraham, David Spetzler
Format:	Artigo
Langue:	Inglês
Publié:	Nature Portfolio 2025-03-01
Collection:	Nature Communications
Accès en ligne:	https://doi.org/10.1038/s41467-025-57941-0
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!